CEL-SCI Corporation 10-Q Summary
Business Context and Reporting Period
This is a quarterly report (Form 10-Q) for CEL-SCI Corporation for the period ended December 31, 1997. The company is a biotechnology firm focused on the human immunological defense system, specifically developing an HIV vaccine and a product called Multikine. The company has not yet realized significant operating revenues and relies on financing activities to fund research and development.
Key Financial Metrics
| Metric | Q1 1998 (Ended Dec 31, 1997) | Q1 1997 (Ended Dec 31, 1996) |
|---|---|---|
| Total Income | $99,599 | $125,045 |
| Net Loss | $(1,605,425) | $(1,181,337) |
| Loss Per Share | $0.14 | $0.14 |
| Cash and Cash Equivalents (End of Period) | $9,814,546 | $4,971,085 |
| Net Cash Used in Operating Activities | $(1,560,120) | $(793,775) |
| Net Cash Provided by Financing Activities | $12,747,922 | $6,912 |
| Total Liabilities | $397,036 | Not explicitly stated for 1996 in table, but current liabilities were $481,587 in prior quarter |
Revenue Composition: Total income consists primarily of interest income ($97,581) and minimal other income ($2,018). There is no product revenue reported.
Expense Breakdown: Research and development expenses were $1,023,312, and general and administrative expenses were $607,787.
Material Changes vs. Prior Period
- Liquidity Improvement: Cash and cash equivalents increased significantly from $3.5 million at the end of the prior quarter (Sept 30, 1997) to $9.8 million at Dec 31, 1997, driven by financing activities.
- Increased Operating Loss: The net loss widened by approximately $424,000 compared to the same period in 1996, primarily due to a 48% increase in R&D expenses.
- Financing Activity: The company raised $9.5 million through the issuance of Series D Preferred Stock and $3.2 million through the issuance of common stock. In the prior year, financing cash flow was negligible ($6,912).
- Investment Portfolio: Investments increased from $745,216 to $5.76 million as the company deployed raised capital into available-for-sale securities.
Outlook, Risks, and Management Commentary
- Capital Dependence: Management states the company does not anticipate significant revenues until licensing arrangements are secured or product sales are permitted, which could take years. The company remains dependent on short-term borrowings and equity sales for liquidity.
- R&D Drivers: Increased R&D spending is attributed to preparations for Phase II Clinical Trials of the HIV vaccine and the addition of two clinical trials for Multikine.
- Recent Financing: On December 23, 1997, the company sold 10,000 shares of convertible preferred stock for $10 million. These shares are convertible at $8.28 per share. Investors also received 1.1 million warrants.
- Warrant Exchange Offer: A subsequent event (Jan-Feb 1998) involves an exchange offer allowing warrant holders to purchase common stock and new warrants at a reduced price ($6.00 for one share and one Series A warrant).
- Risks: The primary risk is the extended timeline to profitability and the continued need for external capital to fund operations and clinical trials.
Investor Verification Checklist
- Verify the status and timeline of the Phase II Clinical Trials for the HIV vaccine and Multikine.
- Confirm the terms and conversion status of the $10 million Series D Preferred Stock issued in December 1997.
- Monitor the company's cash burn rate against its current cash balance of $9.8 million to assess runway.
- Review the details of the warrant exchange offer and its potential dilution impact on common shareholders.
- Check for any updates on licensing agreements that could generate future revenue streams.